IP Library Granted Patent US 10,786,595
Granted Patent B2
US 10,786,595 · App. 14/883,483 · Granted Sep 29, 2020

Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds

Inventors: Dmitry Zimnitsky (Pennington, NJ); Jenny Finkbiner (Helotes, TX); Blane Sanders (San Antonio, TX)
Assignee: KCI Licensing, Inc.
A61L15/64A61K31/385A61K33/18A61K33/38A61K38/17A61K45/06A61L15/26A61L15/32A61L15/44A61L26/0066A61M1/0088A61L2300/21A61L2300/254A61L2300/41A61L2300/412
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,786,595
App. No.
14/883,483
Filed
Oct 14, 2015
Granted
Sep 29, 2020
Kind
B2
Examiner
WENG, KAI H
Art Unit
3781
USPC
424/442
Abstract

According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a topical composition is provided, which can be formulated as a homogenous mixture, such as a spray, mist, aerosol, lotion, cream, solution, oil, gel, ointment, paste, emulsion or suspension or applied on a carrier material, such as a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold. Methods for producing such a topical composition and carrier material with the topical composition applied thereto are also disclosed.

Claims (32)

1. A wound dressing for applying treatment to a tissue site comprising:

a carrier material having a lower portion adapted to contact the tissue site and an upper portion opposite the lower portion; and

a first layer on the carrier material, the first layer comprising a lipoic acid derivative; and

a second layer over the first layer, the second layer comprising a sacrificial proteolytic enzyme substrate.

2. The wound dressing of claim 1 , wherein the sacrificial proteolytic enzyme substrate comprises gelatin.

3. The wound dressing of claim 1 , wherein the carrier material comprises a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold.

4. The wound dressing of claim 1 , wherein the carrier material comprises a bioresorbable material.

5. The wound dressing of claim 4 , wherein the bioresorbable material comprises at least one of polyglycolic acid, polylactic acid, polydioxanone, polyhydroxybutyrate, polyhydrozyvalerate, polyaminoacids polyorthoesters, polyvinly alcohol, collagen, gelatin, chitosan, oxidized regenerated cellulose, hyaluronic acid, or alginate.

6. The wound dressing of claim 1 , wherein the carrier material comprises a non-bioresorbable material.

7. The wound dressing of claim 6 , wherein the non-bioresorbable material comprises at least one of polyurethane, polyvinyl alcohol foam or gauze.

8. The wound dressing of claim 1 , further comprising a drape adapted to be positioned adjacent to the upper portion of the carrier material and provide a fluid seal around the carrier material.

9. The wound dressing of claim 1 , wherein the sacrificial proteolytic enzyme substrate comprises at least one of keratin, collagen, elastin, gelatin, casein, albumin, fibrinogen, fibronectin, soy protein, wheat protein, corn protein, milk proteins and/or hydrolysates thereof.

10. A wound dressing for treating a tissue site, comprising:

a carrier material adapted to contact the tissue site; and

a composition consisting essentially of a first layer of a lipoic acid derivative on the carrier material and a second layer of a sacrificial proteolytic enzyme substrate over the first layer of lipoic acid derivative.

11. The wound dressing of claim 10 , wherein the sacrificial proteolytic enzyme substrate comprises gelatin.

12. The wound dressing of claim 10 , wherein the sacrificial proteolytic enzyme substrate comprises collagen.

13. The wound dressing of claim 10 , wherein the carrier material comprises a polyurethane open-cell foam.

14. The wound dressing of claim 10 , wherein the carrier material comprises a collagen.

15. The wound dressing of claim 10 , wherein:

the carrier material comprises a polyurethane foam; and

the sacrificial proteolytic enzyme substrate comprises gelatin.

16. The wound dressing of claim 10 , wherein the sacrificial proteolytic enzyme substrate comprises at least one of keratin, collagen, elastin, gelatin, casein, albumin, fibrinogen, fibronectin, soy protein, wheat protein, corn protein, milk proteins and/or hydrolysates thereof.

17. A wound dressing for applying treatment to a tissue site comprising:

a carrier material having a lower portion adapted to contact the tissue site and an upper portion opposite the lower portion; and

a lipoic acid derivative and a sacrificial proteolytic enzyme substrate applied to the upper portion of the carrier material;

wherein the lipoic acid derivative is applied to the upper portion of the carrier material as a first layer and the sacrificial proteolytic enzyme substrate is applied as a second layer over the first layer of lipoic acid derivative.

18. The wound dressing of claim 17 , wherein the lipoic acid derivative and the sacrificial proteolytic enzyme substrate form a homogenous mixture.

19. The wound dressing of claim 17 , wherein the sacrificial proteolytic enzyme substrate comprises gelatin.

20. The wound dressing of claim 17 , wherein the carrier material comprises a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold.

21. The wound dressing of claim 17 , wherein the carrier material comprises a bioresorbable material.

22. The wound dressing of claim 21 , wherein the bioresorbable material comprises at least one of polyglycolic acid, polylactic acid, polydioxanone, polyhydroxybutyrate, polyhydrozyvalerate, polyaminoacids polyorthoesters, polyvinly alcohol, collagen, gelatin, chitosan, oxidized regenerated cellulose, hyaluronic acid, or alginate.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: 3M INNOVATIVE PROPERTIES COMPANY
To: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY
Reel/Frame 066432/0376 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2023
From: KCI LICENSING, INC.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 064718/0544 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Nov 7, 2019
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: KCI USA, INC.; KCI LICENSING, INC.
Reel/Frame 050966/0547 →
RELEASE OF SECURITY INTEREST REEL/FRAME 040098/0268 Recorded Feb 8, 2017
From: WILMINGTON TRUST
To: KCI USA, INC.
Reel/Frame 041666/0320 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2015
From: ZIMNITSKY, DMITRY; FINKBINER, JENNY; SANDERS, BLANE
To: KCI LICENSING, INC.
Reel/Frame 036802/0630 →
Continuity (3)
Division 14068961 · Oct 31, 2013
Division 13071387 · Mar 24, 2011
Related Publication 20160101211A1 · Apr 14, 2016
Cited By (5)
US 12,209,206 US 12,269,925 US 12,390,559 US 12,453,804 US 12,697,419